Gemtuzumab ozogamicin (GO) is the only antibody–drug conjugate approved by both the Food and Drug Administration and European Medicines Agency in newly diagnosed and refractory CD33-positive AML for patients aged 1 month or older. This evidence concerns the gene CD33 and acute myeloid leukemia.